UNION Therapeutics to Present at 7th Annual Dermatology Drug Development Summit in Boston

HELLERUP, Denmark, Oct. 25, 2023. UNION Therapeutics A/S (UNION), a leading clinical-stage pharmaceutical development company specializing in immunology and infectious disease, has officially announced its participation in the 7th Annual Dermatology Drug Development Summit, set to take place in Boston from October 31 to November 2, 2023.

Dr. Kim D. Kjøller, the CEO of UNION Therapeutics, will be delivering a presentation during the seminar on clinical trials. The focus of his presentation will be on the recent challenges and advancements in evaluating efficacy in clinical trials for hidradenitis suppurativa (HS). He will also explore the potential benefits of employing novel endpoints to enhance the trial methodology. To provide context for this discussion, Dr. Kjøller will reference data from the OSIRIS proof-of-concept study of oral orismilast in HS, which was initially presented at the European Academy of Dermatology and Venereology (EADV) Congress in 2023.

Details of Dr. Kjøller’s presentation at the 7th Annual Dermatology Drug Development Summit are as follows:

Event: 7th Annual Dermatology Drug Development Summit

Presentation: Demonstrating Efficacy in Clinical Trials with Novel and Meaningful Endpoints

Presenter: Dr. Kim D. Kjøller, CEO, UNION Therapeutics

Date and Time: Wednesday, November 1, 2023, at 10:40 am EST

For further information, please contact:

Morten Boesen Chief Financial Officer, UNION Therapeutics A/S Phone: +45 2381 5487 Email: morten.boesen@uniontherapeutics.com

Sarah Toft-Jørgensen Director of Communications and IR, UNION Therapeutics A/S Phone: +45 5385 3044 Email: stj@uniontherapeutics.com

About UNION Therapeutics:

UNION Therapeutics A/S is a privately held pharmaceutical development company based in Denmark, specializing in clinical-stage research in the fields of immunology and infectious diseases. The company is committed to advancing medical solutions to address pressing global health challenges. For more information, please visit UNION Therapeutics.

Related posts:

Zevra Therapeutics Makes Strategic Leap into Rare Disease Market with Acer Therapeutics Acquisition Sage Therapeutics Announces Major Restructuring Following Zurzuvae FDA Approval ADC Therapeutics Discontinues Zynlonta Trial After 7 Deaths Led to An FDA Partial Hold Innovative Anti-Tumor Drug, LX-039, Shows Promise in Phase I Clinical Study Data Presented at ESMO 2023